- Home
- GROW vs TPST Comparison
GROW vs TPST Comparison
Compare GROW & TPST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GROW | TPST |
|---|---|---|
| Founded | 1968 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 32.7M | 26.2M |
| IPO Year | 1995 | 2012 |
Fundamental Metrics
Financial Performance| Metric | GROW | TPST |
|---|---|---|
| Price | $2.91 | $1.25 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $11.00 |
| AVG Volume (30 Days) | 28.6K | ★ 88.4K |
| Earning Date | 05-11-2026 | 05-08-2026 |
| Dividend Yield | ★ 3.53% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.27 | N/A |
| Revenue | ★ $23,850,609.00 | $295,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $11.07 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.23 | $1.23 |
| 52 Week High | $3.65 | $12.22 |
Technical Indicators
Market Signals| Indicator | GROW | TPST |
|---|---|---|
| Relative Strength Index (RSI) | 71.32 | 30.75 |
| Support Level | $2.39 | $1.23 |
| Resistance Level | $3.43 | $2.48 |
| Average True Range (ATR) | 0.08 | 0.07 |
| MACD | 0.04 | -0.01 |
| Stochastic Oscillator | 87.00 | 5.30 |
Price Performance
Historical ComparisonAbout GROW U.S. Global Investors Inc.
US Global Investors Inc is a registered investment advisory firm. The company manages the following business segments: Investment management services; through which the company offers, to U.S. Global Investors Funds (USGIF or the Funds) and exchange-traded fund (ETF) clients, a range of investment management products and services to meet the needs of individual and institutional investors; and Corporate Investments, through which the company invests for its own account in an effort to add growth and value to its cash position. It derives all its revenue from Investment management services.
About TPST Tempest Therapeutics Inc.
Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets. Company's small-molecule product candidate, amezalpat (previously known as TPST-1120), has completed a Phase 2 study in first-line hepatocellular carcinoma and the second small-molecule product candidate is TPST-1495, plans to initiate a Phase 2 study for in familial adenomatous polyposis.